We already know that the MACE reduction in the CKD subgroup was amazing. For sure, Dr. Kalantar-Zadeh will emphasize that and go into further detail. As for the other measures, including change in eGFR, in the CKD sub-study, we will have to wait and see. Everyone's been hush hush on the CKD sub-study, probably due to embargo reasons.

Here is a poster that describes in more detail the CKD sub-study.

And if you need a refresher on the MACE reduction in the CKD sub-study, browse through slides 19-29 in the post-AHA company presentation.